A First Step to a Biomarker of Curative Surgery in Colorectal Cancer by Liquid Biopsy of Methylated Septin 9 Gene
Objectives. To confirm that patients affected by colorectal cancer have the V2 region of Septin 9 (SEPT9) gene hypermethylated in the circulating free DNA from a peripheral blood sample before surgery and to determine if this hypermethylated DNA disappears from the patients after complete resection...
Gespeichert in:
| Veröffentlicht in: | Disease markers 2020, Vol.2020 (2020), p.1-5 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5 |
|---|---|
| container_issue | 2020 |
| container_start_page | 1 |
| container_title | Disease markers |
| container_volume | 2020 |
| creator | García-Olmo, D. Guadalajara, H. Olmedillas-Lopez, S. Magallares, S. Olivera, R. Ruiz, R. García-Arranz, M. Leon Arellano, M. Valdes-Sanchez, T. |
| description | Objectives. To confirm that patients affected by colorectal cancer have the V2 region of Septin 9 (SEPT9) gene hypermethylated in the circulating free DNA from a peripheral blood sample before surgery and to determine if this hypermethylated DNA disappears from the patients after complete resection of the tumour. Methods. Plasma from 10 patients with colorectal cancer was collected preoperative and three months after surgery. The analysis of the methylation status of the promoter region of the SEPT9 gene was performed using a 7500 Fast Real-Time PCR System. Results. Hypermethylation of SEPT9 gene was detected in 8 out of 10 preoperative samples (one negative result was probed to be a Lynch syndrome) and in 4 out of 10 postoperative samples matching with the cases of recurrence or persistence of disease. This means that, in this sample, the preoperative sensitivity and specificity of the test were 88.9% and 100%, respectively, and there is 100% correlation between the positive results of the SEPT9 test and a recurrence/persistence of the disease in patients after surgical resection. Conclusions. Our study shows that circulating hypermethylated SEPT9 is a specific colorectal cancer biomarker. This hypermethylated SEPT9 DNA disappears around three months after surgery and that circulating hypermethylated SEPT9 may be the first noninvasive marker for postsurgical diagnosis; this conclusion must be confirmed with a more significant number of patients. |
| doi_str_mv | 10.1155/2020/9761406 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7293729</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A632853510</galeid><sourcerecordid>A632853510</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-94477bf90c84937f7ecb7c0146bb043e787e9092d92f006d77d807514ed718ee3</originalsourceid><addsrcrecordid>eNqN0U2P0zAQBmALgdhSuHFGlrggQVl_xvZlpVKxC1IRh8LZcpJJ6yWNW8dZlH-Po5Zd4MTB8sHPvOPRIPSSkveUSnnJCCOXRhVUkOIRmlGt5EIXnDxGM8KUXhAmyAV61ve3hFBmhHmKLjiTRUEEm6HjEl_72Ce8SXDAKWCHP_iwd_EHRBwavBqiS_4O8GaIW4gj9h1ehTZEqJJr8cp1VYbliNf-OPh6Kj7041T5BdJubF2CGm_gkHKdwTfQwXP0pHFtDy_O9xx9v_74bfVpsf5683m1XC8qYUxaGCGUKhtDKi0MV42CqlQVoaIoSyI4KK3AEMNqwxpCilqpWhMlqYBaUQ3A5-jqlHsYyj3UFXQputYeos_TjTY4b_9-6fzObsOdVSz3y2eO3pwDYjgO0Ce7930Fbes6CENvmaBSc1Fonunrf-htGGKXx5sU01xKox7U1rVgfdeE3LeaQu2y4ExLLinJ6t1JVTH0fYTm_suU2Gnjdtq4PW8881d_jnmPf684g7cnsPNd7X76_4yDbKBxD5rKHCb4L99mupg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2412835597</pqid></control><display><type>article</type><title>A First Step to a Biomarker of Curative Surgery in Colorectal Cancer by Liquid Biopsy of Methylated Septin 9 Gene</title><source>MEDLINE</source><source>Wiley-Blackwell Titles (Open access)</source><source>PubMed Central(OpenAccess)</source><source>EZB Free E-Journals</source><source>Alma/SFX Local Collection</source><creator>García-Olmo, D. ; Guadalajara, H. ; Olmedillas-Lopez, S. ; Magallares, S. ; Olivera, R. ; Ruiz, R. ; García-Arranz, M. ; Leon Arellano, M. ; Valdes-Sanchez, T.</creator><contributor>Cantile, Monica ; Monica Cantile</contributor><creatorcontrib>García-Olmo, D. ; Guadalajara, H. ; Olmedillas-Lopez, S. ; Magallares, S. ; Olivera, R. ; Ruiz, R. ; García-Arranz, M. ; Leon Arellano, M. ; Valdes-Sanchez, T. ; Cantile, Monica ; Monica Cantile</creatorcontrib><description>Objectives. To confirm that patients affected by colorectal cancer have the V2 region of Septin 9 (SEPT9) gene hypermethylated in the circulating free DNA from a peripheral blood sample before surgery and to determine if this hypermethylated DNA disappears from the patients after complete resection of the tumour. Methods. Plasma from 10 patients with colorectal cancer was collected preoperative and three months after surgery. The analysis of the methylation status of the promoter region of the SEPT9 gene was performed using a 7500 Fast Real-Time PCR System. Results. Hypermethylation of SEPT9 gene was detected in 8 out of 10 preoperative samples (one negative result was probed to be a Lynch syndrome) and in 4 out of 10 postoperative samples matching with the cases of recurrence or persistence of disease. This means that, in this sample, the preoperative sensitivity and specificity of the test were 88.9% and 100%, respectively, and there is 100% correlation between the positive results of the SEPT9 test and a recurrence/persistence of the disease in patients after surgical resection. Conclusions. Our study shows that circulating hypermethylated SEPT9 is a specific colorectal cancer biomarker. This hypermethylated SEPT9 DNA disappears around three months after surgery and that circulating hypermethylated SEPT9 may be the first noninvasive marker for postsurgical diagnosis; this conclusion must be confirmed with a more significant number of patients.</description><identifier>ISSN: 0278-0240</identifier><identifier>EISSN: 1875-8630</identifier><identifier>DOI: 10.1155/2020/9761406</identifier><identifier>PMID: 32566042</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Aged ; Biomarkers ; Biomarkers, Tumor - blood ; Biomarkers, Tumor - genetics ; Biopsy ; Blood circulation ; Cancer ; Cancer therapies ; Cell division ; Colorectal cancer ; Colorectal carcinoma ; Colorectal Neoplasms - blood ; Colorectal Neoplasms - genetics ; Colorectal Neoplasms - pathology ; Colorectal Neoplasms - surgery ; Deoxyribonucleic acid ; Diseases ; DNA ; DNA Methylation ; Epigenetics ; Ethylenediaminetetraacetic acid ; Female ; Genes ; Genetic aspects ; Humans ; Liquid Biopsy - methods ; Male ; Medical prognosis ; Methylation ; Middle Aged ; Neoplasm Recurrence, Local - blood ; Neoplasm Recurrence, Local - genetics ; Oncology, Experimental ; Patients ; Peripheral blood ; Plasma ; Postoperative Complications - blood ; Postoperative Complications - genetics ; Radiation therapy ; Relapse ; Septin ; Septins - blood ; Septins - genetics ; Surgery ; Surveillance ; Tumors</subject><ispartof>Disease markers, 2020, Vol.2020 (2020), p.1-5</ispartof><rights>Copyright © 2020 M. Leon Arellano et al.</rights><rights>COPYRIGHT 2020 John Wiley & Sons, Inc.</rights><rights>Copyright © 2020 M. Leon Arellano et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. http://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2020 M. Leon Arellano et al. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c499t-94477bf90c84937f7ecb7c0146bb043e787e9092d92f006d77d807514ed718ee3</citedby><cites>FETCH-LOGICAL-c499t-94477bf90c84937f7ecb7c0146bb043e787e9092d92f006d77d807514ed718ee3</cites><orcidid>0000-0002-9369-2338 ; 0000-0002-6266-9055 ; 0000-0001-6297-9347 ; 0000-0002-9681-3203 ; 0000-0002-6535-5852</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293729/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293729/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4024,27923,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32566042$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Cantile, Monica</contributor><contributor>Monica Cantile</contributor><creatorcontrib>García-Olmo, D.</creatorcontrib><creatorcontrib>Guadalajara, H.</creatorcontrib><creatorcontrib>Olmedillas-Lopez, S.</creatorcontrib><creatorcontrib>Magallares, S.</creatorcontrib><creatorcontrib>Olivera, R.</creatorcontrib><creatorcontrib>Ruiz, R.</creatorcontrib><creatorcontrib>García-Arranz, M.</creatorcontrib><creatorcontrib>Leon Arellano, M.</creatorcontrib><creatorcontrib>Valdes-Sanchez, T.</creatorcontrib><title>A First Step to a Biomarker of Curative Surgery in Colorectal Cancer by Liquid Biopsy of Methylated Septin 9 Gene</title><title>Disease markers</title><addtitle>Dis Markers</addtitle><description>Objectives. To confirm that patients affected by colorectal cancer have the V2 region of Septin 9 (SEPT9) gene hypermethylated in the circulating free DNA from a peripheral blood sample before surgery and to determine if this hypermethylated DNA disappears from the patients after complete resection of the tumour. Methods. Plasma from 10 patients with colorectal cancer was collected preoperative and three months after surgery. The analysis of the methylation status of the promoter region of the SEPT9 gene was performed using a 7500 Fast Real-Time PCR System. Results. Hypermethylation of SEPT9 gene was detected in 8 out of 10 preoperative samples (one negative result was probed to be a Lynch syndrome) and in 4 out of 10 postoperative samples matching with the cases of recurrence or persistence of disease. This means that, in this sample, the preoperative sensitivity and specificity of the test were 88.9% and 100%, respectively, and there is 100% correlation between the positive results of the SEPT9 test and a recurrence/persistence of the disease in patients after surgical resection. Conclusions. Our study shows that circulating hypermethylated SEPT9 is a specific colorectal cancer biomarker. This hypermethylated SEPT9 DNA disappears around three months after surgery and that circulating hypermethylated SEPT9 may be the first noninvasive marker for postsurgical diagnosis; this conclusion must be confirmed with a more significant number of patients.</description><subject>Aged</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biopsy</subject><subject>Blood circulation</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Cell division</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Colorectal Neoplasms - blood</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Colorectal Neoplasms - surgery</subject><subject>Deoxyribonucleic acid</subject><subject>Diseases</subject><subject>DNA</subject><subject>DNA Methylation</subject><subject>Epigenetics</subject><subject>Ethylenediaminetetraacetic acid</subject><subject>Female</subject><subject>Genes</subject><subject>Genetic aspects</subject><subject>Humans</subject><subject>Liquid Biopsy - methods</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Methylation</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - blood</subject><subject>Neoplasm Recurrence, Local - genetics</subject><subject>Oncology, Experimental</subject><subject>Patients</subject><subject>Peripheral blood</subject><subject>Plasma</subject><subject>Postoperative Complications - blood</subject><subject>Postoperative Complications - genetics</subject><subject>Radiation therapy</subject><subject>Relapse</subject><subject>Septin</subject><subject>Septins - blood</subject><subject>Septins - genetics</subject><subject>Surgery</subject><subject>Surveillance</subject><subject>Tumors</subject><issn>0278-0240</issn><issn>1875-8630</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><recordid>eNqN0U2P0zAQBmALgdhSuHFGlrggQVl_xvZlpVKxC1IRh8LZcpJJ6yWNW8dZlH-Po5Zd4MTB8sHPvOPRIPSSkveUSnnJCCOXRhVUkOIRmlGt5EIXnDxGM8KUXhAmyAV61ve3hFBmhHmKLjiTRUEEm6HjEl_72Ce8SXDAKWCHP_iwd_EHRBwavBqiS_4O8GaIW4gj9h1ehTZEqJJr8cp1VYbliNf-OPh6Kj7041T5BdJubF2CGm_gkHKdwTfQwXP0pHFtDy_O9xx9v_74bfVpsf5683m1XC8qYUxaGCGUKhtDKi0MV42CqlQVoaIoSyI4KK3AEMNqwxpCilqpWhMlqYBaUQ3A5-jqlHsYyj3UFXQputYeos_TjTY4b_9-6fzObsOdVSz3y2eO3pwDYjgO0Ce7930Fbes6CENvmaBSc1Fonunrf-htGGKXx5sU01xKox7U1rVgfdeE3LeaQu2y4ExLLinJ6t1JVTH0fYTm_suU2Gnjdtq4PW8881d_jnmPf684g7cnsPNd7X76_4yDbKBxD5rKHCb4L99mupg</recordid><startdate>2020</startdate><enddate>2020</enddate><creator>García-Olmo, D.</creator><creator>Guadalajara, H.</creator><creator>Olmedillas-Lopez, S.</creator><creator>Magallares, S.</creator><creator>Olivera, R.</creator><creator>Ruiz, R.</creator><creator>García-Arranz, M.</creator><creator>Leon Arellano, M.</creator><creator>Valdes-Sanchez, T.</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7TK</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9369-2338</orcidid><orcidid>https://orcid.org/0000-0002-6266-9055</orcidid><orcidid>https://orcid.org/0000-0001-6297-9347</orcidid><orcidid>https://orcid.org/0000-0002-9681-3203</orcidid><orcidid>https://orcid.org/0000-0002-6535-5852</orcidid></search><sort><creationdate>2020</creationdate><title>A First Step to a Biomarker of Curative Surgery in Colorectal Cancer by Liquid Biopsy of Methylated Septin 9 Gene</title><author>García-Olmo, D. ; Guadalajara, H. ; Olmedillas-Lopez, S. ; Magallares, S. ; Olivera, R. ; Ruiz, R. ; García-Arranz, M. ; Leon Arellano, M. ; Valdes-Sanchez, T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-94477bf90c84937f7ecb7c0146bb043e787e9092d92f006d77d807514ed718ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biopsy</topic><topic>Blood circulation</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Cell division</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Colorectal Neoplasms - blood</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Colorectal Neoplasms - surgery</topic><topic>Deoxyribonucleic acid</topic><topic>Diseases</topic><topic>DNA</topic><topic>DNA Methylation</topic><topic>Epigenetics</topic><topic>Ethylenediaminetetraacetic acid</topic><topic>Female</topic><topic>Genes</topic><topic>Genetic aspects</topic><topic>Humans</topic><topic>Liquid Biopsy - methods</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Methylation</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - blood</topic><topic>Neoplasm Recurrence, Local - genetics</topic><topic>Oncology, Experimental</topic><topic>Patients</topic><topic>Peripheral blood</topic><topic>Plasma</topic><topic>Postoperative Complications - blood</topic><topic>Postoperative Complications - genetics</topic><topic>Radiation therapy</topic><topic>Relapse</topic><topic>Septin</topic><topic>Septins - blood</topic><topic>Septins - genetics</topic><topic>Surgery</topic><topic>Surveillance</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>García-Olmo, D.</creatorcontrib><creatorcontrib>Guadalajara, H.</creatorcontrib><creatorcontrib>Olmedillas-Lopez, S.</creatorcontrib><creatorcontrib>Magallares, S.</creatorcontrib><creatorcontrib>Olivera, R.</creatorcontrib><creatorcontrib>Ruiz, R.</creatorcontrib><creatorcontrib>García-Arranz, M.</creatorcontrib><creatorcontrib>Leon Arellano, M.</creatorcontrib><creatorcontrib>Valdes-Sanchez, T.</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Disease markers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>García-Olmo, D.</au><au>Guadalajara, H.</au><au>Olmedillas-Lopez, S.</au><au>Magallares, S.</au><au>Olivera, R.</au><au>Ruiz, R.</au><au>García-Arranz, M.</au><au>Leon Arellano, M.</au><au>Valdes-Sanchez, T.</au><au>Cantile, Monica</au><au>Monica Cantile</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A First Step to a Biomarker of Curative Surgery in Colorectal Cancer by Liquid Biopsy of Methylated Septin 9 Gene</atitle><jtitle>Disease markers</jtitle><addtitle>Dis Markers</addtitle><date>2020</date><risdate>2020</risdate><volume>2020</volume><issue>2020</issue><spage>1</spage><epage>5</epage><pages>1-5</pages><issn>0278-0240</issn><eissn>1875-8630</eissn><abstract>Objectives. To confirm that patients affected by colorectal cancer have the V2 region of Septin 9 (SEPT9) gene hypermethylated in the circulating free DNA from a peripheral blood sample before surgery and to determine if this hypermethylated DNA disappears from the patients after complete resection of the tumour. Methods. Plasma from 10 patients with colorectal cancer was collected preoperative and three months after surgery. The analysis of the methylation status of the promoter region of the SEPT9 gene was performed using a 7500 Fast Real-Time PCR System. Results. Hypermethylation of SEPT9 gene was detected in 8 out of 10 preoperative samples (one negative result was probed to be a Lynch syndrome) and in 4 out of 10 postoperative samples matching with the cases of recurrence or persistence of disease. This means that, in this sample, the preoperative sensitivity and specificity of the test were 88.9% and 100%, respectively, and there is 100% correlation between the positive results of the SEPT9 test and a recurrence/persistence of the disease in patients after surgical resection. Conclusions. Our study shows that circulating hypermethylated SEPT9 is a specific colorectal cancer biomarker. This hypermethylated SEPT9 DNA disappears around three months after surgery and that circulating hypermethylated SEPT9 may be the first noninvasive marker for postsurgical diagnosis; this conclusion must be confirmed with a more significant number of patients.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>32566042</pmid><doi>10.1155/2020/9761406</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-9369-2338</orcidid><orcidid>https://orcid.org/0000-0002-6266-9055</orcidid><orcidid>https://orcid.org/0000-0001-6297-9347</orcidid><orcidid>https://orcid.org/0000-0002-9681-3203</orcidid><orcidid>https://orcid.org/0000-0002-6535-5852</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-0240 |
| ispartof | Disease markers, 2020, Vol.2020 (2020), p.1-5 |
| issn | 0278-0240 1875-8630 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7293729 |
| source | MEDLINE; Wiley-Blackwell Titles (Open access); PubMed Central(OpenAccess); EZB Free E-Journals; Alma/SFX Local Collection |
| subjects | Aged Biomarkers Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Biopsy Blood circulation Cancer Cancer therapies Cell division Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - blood Colorectal Neoplasms - genetics Colorectal Neoplasms - pathology Colorectal Neoplasms - surgery Deoxyribonucleic acid Diseases DNA DNA Methylation Epigenetics Ethylenediaminetetraacetic acid Female Genes Genetic aspects Humans Liquid Biopsy - methods Male Medical prognosis Methylation Middle Aged Neoplasm Recurrence, Local - blood Neoplasm Recurrence, Local - genetics Oncology, Experimental Patients Peripheral blood Plasma Postoperative Complications - blood Postoperative Complications - genetics Radiation therapy Relapse Septin Septins - blood Septins - genetics Surgery Surveillance Tumors |
| title | A First Step to a Biomarker of Curative Surgery in Colorectal Cancer by Liquid Biopsy of Methylated Septin 9 Gene |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T07%3A45%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20First%20Step%20to%20a%20Biomarker%20of%20Curative%20Surgery%20in%20Colorectal%20Cancer%20by%20Liquid%20Biopsy%20of%20Methylated%20Septin%209%20Gene&rft.jtitle=Disease%20markers&rft.au=Garc%C3%ADa-Olmo,%20D.&rft.date=2020&rft.volume=2020&rft.issue=2020&rft.spage=1&rft.epage=5&rft.pages=1-5&rft.issn=0278-0240&rft.eissn=1875-8630&rft_id=info:doi/10.1155/2020/9761406&rft_dat=%3Cgale_pubme%3EA632853510%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2412835597&rft_id=info:pmid/32566042&rft_galeid=A632853510&rfr_iscdi=true |